BioCentury | Nov 30, 2018
Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

...option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib...
...equity financing and R&D funding for a global Phase III trial of topical patidegib (saridegib, IPI-926...
...Leo Pharma A/S, Ballerup, Denmark BridgeBio Pharma LLC, Palo Alto, Calif. Business: Dermatology Mary Romeo patidegib, saridegib (IPI-926) Leo...
BioCentury | Nov 20, 2018
Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

...option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib...
...equity financing and R&D funding for a global Phase III trial of topical patidegib (saridegib, IPI-926...
...PellePharm's board. PellePharm is a subsidiary of BridgeBio Pharma LLC (Palo Alto, Calif.). Mary Romeo patidegib, saridegib (IPI-926) Leo...
BioCentury | Sep 15, 2017
Finance

Orphan opportunity

...preclinical. PellePharm Inc. plans to begin a Phase III trial of topical smoothened (SMO) inhibitor patidegib...
BioCentury | Sep 15, 2017
Financial News

BridgeBio raises $135M round

...and Phoenix Tissue Repair Inc. PellePharm plans to begin a Phase III trial of topical patidegib...
...to disclose how much BridgeBio has raised in total. BridgeBio Pharma , Palo Alto, Calif. Jennie Walters AG10 patidegib Infinity...
BioCentury | Sep 13, 2017
Financial News

BridgeBio raises $135M round

...and Phoenix Tissue Repair Inc. PellePharm plans to begin a Phase III trial of topical patidegib...
BioCentury | Sep 1, 2017
Clinical News

PellePharm reports Phase II data of patidegib for Gorlin Syndrome

...Phase II trial in 17 patients with Gorlin Syndrome showing that twice-daily topical patidegib (saridegib, IPI-926...
...non-central facial carcinomas. PellePharm plans to start a Phase III trial of patidegib in 1H18. Patidegib...
...Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. PellePharm Inc. , Menlo Park, Calif. Product: Patidegib (Saridegib, IPI-926...
BioCentury | Apr 29, 2017
Finance

Coming out party

...complete Phase II trials by YE18. BridgeBio’s other disclosed subsidiary, PellePharm Inc. , is developing patidegib...
BioCentury | Sep 8, 2014
Strategy

PI(3)King AbbVie

...The prior year, Infinity reduced headcount by 20% after discontinuing development of hedgehog pathway inhibitor saridegib...
BioCentury | Jun 12, 2014
Targets & Mechanisms

Stromal uncertainties in pancreatic cancer

...tumor stroma. The group showed that the small molecule smoothened ( SMO ) inhibitor saridegib (IPI-926...
...mediator of hedgehog pathway signaling. The following year, Infinity began a Phase I/IIb trial of saridegib...
...and lower overall survival than patients receiving placebo plus gemcitabine. The company discontinued development of saridegib...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Cancer

...of a-Sma+ stromal myofibroblasts, knocking out Shh or blocking hedgehog signaling with the SMO inhibitor saridegib...
...stroma- and fibrosis-depleting drugs such as SMO inhibitors could have benefit. Infinity Pharmaceuticals Inc. discontinued saridegib...
Items per page:
1 - 10 of 60